Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients
Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients
08 Apr 2026 bởiAudrey Abella

In the prespecified subgroup analysis of the VESALIUS-CV trial, evolocumab significantly reduced the risk of first major adverse cardiovascular (CV) events (MACE) in individuals without known significant atherosclerosis and with diabetes.

Early intensive lipid-lowering with evolocumab cuts CV events in high-risk primary prevention patients
08 Apr 2026